2,5-二甲基-4,6-嘧啶二胺 | 13265-42-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2,5-二甲基-4,6-嘧啶二胺
• 英文名称: 2,5-dimethyl-pyrimidine-4,6-diyldiamine
• 英文别名: 2,5-Dimethyl-pyrimidin-4,6-diyldiamin；2,5-Dimethylpyrimidine-4,6-diamine
• CAS: 13265-42-4
• 化学式: C₆H₁₀N₄
• 分子量: 138.172
• InChiKey: HZZKLBBMUXBGEL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  77.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  6-氯-2,5-二甲基-嘧啶-4-胺 在 乙醇 、 氨 、 水 作用下， 生成 2,5-二甲基-4,6-嘧啶二胺
  参考文献：
  名称：

  Huber; Hoelscher, Chemische Berichte, 1938, vol. 71, p. 87,99

  摘要：

  DOI：

文献信息

• CALCIUM CHANNEL ANTAGONISTS
  申请人：Pacofsky J. Gregory

  公开号：US20070197523A1

  公开（公告）日：2007-08-23

  The present invention provides novel calcium channel antagonists, and methods of treating disease sates using the novel antagonists.

  本发明提供了新型钙通道拮抗剂，并使用这些新型拮抗剂治疗疾病状态的方法。
• IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
  申请人：Lai Yingjie

  公开号：US20130096104A1

  公开（公告）日：2013-04-18

  The invention provides compounds of Formulas Ia-Ib, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, X, R 1 , R 2 , R 4 , R 5 and R 16 are defined herein, a pharmaceutical composition that includes a compound of Formulas Ia-Ib and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of using the compound or composition in therapy, as an inhibitor of TYK2 kinase and conditions related, such as inflammatory illnesses, inflammatory bowel disease or psoriasis.

  本发明提供了公式Ia-Ib的化合物、立体异构体或其药学上可接受的盐，其中A、X、R1、R2、R4、R5和R16在此定义，一种包括公式Ia-Ib化合物和药学上可接受的载体、佐剂或车载物的药物组合物，以及使用该化合物或组合物作为TYK2激酶的抑制剂和相关疾病的治疗方法，例如炎症性疾病、炎症性肠病或牛皮癣。
• Researches on Pyrimidines: Certain Derivatives of 2-Methylpyrimidine
  作者：Henry R. Henze、William J. Clegg、Charles W. Smart

  DOI：10.1021/jo50010a007

  日期：1952.10
• Inhibitors of RHO Associated Coiled-Coil Containing Protein Kinase
  申请人：Kadmon Corporation, LLC

  公开号：US20200199109A1

  公开（公告）日：2020-06-25

  The invention relates to inhibitors of ROCK1 and/or ROCK2. Also provided are methods of inhibiting ROCK1 and/or ROCK2 that are useful for the treatment of disease.
• [EN] 2,4,6-TRIAMINOPYRIMIDINES FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY<br/>[FR] 2,4,6-TRIAMINOPYRIMIDINES UTILISEES DANS LE TRAITEMENT DE LA DEPRESSION ET/OU DE L'ANXIETE
  申请人：SYNAPTIC PHARMA CORP

  公开号：WO2004034967A2

  公开（公告）日：2004-04-29

  This invention is directed to pyrimidine derivatives which are selective antagonists for the GalR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety. This invention also provides a method of treating depression and/or anxiety in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GalR3 receptor antagonist.